Clinical Trial Update: Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating prophylactic donor lymphocyte infusion to prevent relapse after allogeneic stem cell transplant in high-risk myeloid malignanc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia Myeloid Acute
• Myelodysplastic Syndromes

Drugs mentioned

• Donor Lymphocyte Infusion

Snippet

Sponsor: King's College Hospital NHS Trust | Conditions: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute | Phase 2 | Status: UNKNOWN